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Abstract
Background: Sepsis is a life-threatening condition and major contributor of public health and economic burden in
the industrialised world. The heterogeneity, absence of more specific definition, and difficulties in accurate diagnosis
lead to great variability in the estimates of sepsis incidence. There has been uncertainty regarding the incidence and
risk factors attributable to community-onset as opposed to hospital-acquired sepsis. Community-onset sepsis has
distinct host characteristics, risk factors, pathogens, and prognosis. A systematic assessment of recent evidence is
warranted in light of secular changes in epidemiology, pathogens, and the uncertainties around the incidence and risk
factors of community-onset sepsis.
This protocol describes a systematic review which aims to synthesise the recent empirical evidence on
the incidence and risk factors of community-onset sepsis, severe sepsis, and septic shock in high-income
countries.
Methods/Design: English-language publications of cohort and case-control studies reporting incidence and
risk factors of community-onset sepsis will be eligible for inclusion. MEDLINE and Embase databases will be
searched from 2002 and onwards. References of relevant publications will be hand-searched. Two reviewers
will independently screen titles/abstracts and full texts as well as extract data and appraise the risk of bias of
included studies. The data extractions and risk of bias assessments will be cross-checked. Any disagreements will be
resolved via consensus.
The data on incidence and risk factors of sepsis will be organised and synthesised in text, tables, and forest plots. The
evidence will be pooled given sufficient data and degree of similarity across study populations, exposures, and outcomes.
The heterogeneity will be assessed through visual inspection of forest plots, Chi-square-based p value, and I2 statistic. The
sources of heterogeneity will be explored via subgroup analysis.
Discussion: Timeliness and accuracy of diagnosis of sepsis are both crucial aspects for improving the patient’s outcome.
The findings of this review will be discussed with a view to better inform future recommendations on
improving public-facing campaigns, timely presentation, and diagnosis of sepsis in the community. The review will
also discuss gaps in evidence and highlight future research and policy-making avenues for improving public health
planning.
Systematic review registration: PROSPERO CRD42015023484
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Background
Context for this review
The UK Department of Health allocated the task to
‘Review the evidence and make recommendations on the
scope for a public-facing campaign to raise awareness
of Sepsis.’ (https://www.gov.uk/government/publications/
phe-remit-letter-2015-to-2016) to Public Health England
in the 2015–2016 remit letter to PHE. The University of
Warwick was requested to synthesise relevant evidence in-
cluding estimating the burden of community-onset sepsis
and groups affected by community-onset sepsis. This is
the motivation for this work.
Health and economic burden
Sepsis is a complex life-threatening condition charac-
terised by the host’s systemic anti-inflammatory immune
response to infection, which may lead to organ damage,
organ failure, septic shock, and death [1]. Sepsis with its
associated complications remains a major public health
and economic burden in the industrialised world [2].
Outcomes of sepsis may have serious short- or long-term
consequences such as amputation, damage to organs, or
cognitive dysfunction. In the US, treatment of a patient
with sepsis may cost up to $50,000, translating to an an-
nual nationwide economic burden of $17 billion [3, 4]. In
European studies, the treatment of severe sepsis in 2002
was estimated to be approximately £25,000 [5]. Assuming
the incidence of 100,000 new cases per year, the UK’s
National Health System (NHS) expenditure for caring
these cases would amount to £2.5 billion annually [6].
Data on global incidence of sepsis is scarce but has been
growing over the past two decades, with the majority of
studies identifying sepsis cases from intensive-care unit
(ICU) data [4]. The estimates of sepsis incidence are
highly variable. This is likely due to the heterogeneous na-
ture, lack of a uniform definition, and difficulties in the ac-
curate diagnosis of the condition as well as the differences
in data sources (e.g. clinical registries, hospital discharge
databases, or vital statistics records), periods of follow-up
time, and methods of estimation used across studies.
Moreover, secular changes and genuine differences in the
incidence of sepsis across study populations may have
additionally contributed to the observed variability. For
example, one systematic review [7] reported the following
ranges of annual incidence for sepsis (149–240 per
100,000 population) and severe sepsis (56–91 per 100,000
population). Another more recent systematic review of 33
epidemiologic studies conducted in 15 high-income coun-
tries [8] estimated and reported an average incidence of
427 (95 % CI 281, 648) for sepsis and 331 (95 % CI 207,
530) for severe sepsis cases per 100,000 person-years.
Large nationwide cohort studies conducted in five high-
income countries (the USA, the UK, France, Australia, and
New Zealand) in 1995–2002 showed a wide variation in the
annual incidence of severe sepsis, ranging from 51 [9] to
300 [3] cases per 100,000 population [4, 3, 9–11]. The study
by Padkin et al. [9] which reviewed data from 91 ICUs
across England, Wales, and Northern Ireland reported an
annual incidence of 51 cases of severe sepsis per 100,000
persons. These findings are in agreement with another UK-
based cohort study which reported an incidence of 66 cases
per 100,000 per population [12]. More recent studies con-
ducted in Europe reported lower incidence rates of 38 [13]
and 25 cases [14] per 100,000 population. Although variable,
the results of these nationwide cohort studies nonetheless
all indicate that severe sepsis is a common disorder [2].
Recent estimates of case-fatality rates for sepsis ranged
from 14.7 % [15] to 28.6 % [3] in the US-based studies [3, 4,
15] and from 35.0 % [11] to 53.6 % [16] in European studies
[11, 16, 10, 9, 5]. Almost one third of all ICU admissions in
the UK are related to sepsis and about half of these patients
die [9]. In their study [17], McPherson and colleagues re-
ported that one in 20 deaths in England in 2001–2010 was
associated with sepsis. These figures may underestimate the
true mortality rate. Sepsis is often underreported as a cause
of death because of the absence of the sepsis-specific Inter-
national Classification of Diseases, 10th Revision (ICD-10)
codes. Therefore, the sepsis-related deaths are often coded
as deaths caused by kidney infection, pneumonia, influenza,
or meningitis [17].
Over the past two decades, there has been accumulation
of empirical evidence showing a gradual increase (8–13 %
per year) in the incidence of sepsis in high-income coun-
tries (e.g. the UK, Australia, Croatia) [18], especially in the
USA [4, 12, 19]. For example, one UK-based cohort study
found an increase in annual incidence of severe sepsis
from 46 (in 1996) to 66 cases per 100,000 per population
between 1996 and 2003 [12]. In contrast to the incidence
data, the mortality (i.e. case-fatality rate) after sepsis in
high-income countries has been decreasing [15, 20]. For
example, one US-based study reported the decrease in
case-fatality rate of sepsis from 27.8 % (1979–1984) to
17.9 % (1995–2000) [4]. Similarly, in their ICU-based
study [12], Harrison et al. showed a significant decrease in
mortality rate from 48.3 % (in 1996) to 44.7 % (in 2004).
The observed trends of rising incidence could be due to
increased proportions of high-risk population subgroups
(e.g. elderly, type-II diabetes, antibiotic resistance, cancer),
improvements in methods of detection [21, 22], and the
falling mortality rates due to identification of less severe
forms of sepsis (in light of the improved methods of detec-
tion) [21, 22] and/or advancements in the treatment of
sepsis [23, 12, 22]. In spite of the reduced case-fatality rates,
the total annual number of sepsis-related deaths has been
rising, perhaps owing to the increased incidence of sepsis
[18]. Over the last two decades, Gram-positive bacteria
have superseded Gram-negative bacteria as the most
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common cause of sepsis as further evidence of the changing
biology of this condition [18].
Definition and diagnosis
Sepsis treatment is time-critical, which necessitates timely
diagnosis and rapid provision of appropriate management
options. However, this is made difficult owing to the het-
erogeneity of this condition, often characterised by non-
specific clinical features. The current definition of ‘sepsis’
which was introduced in 1991 [24] encompasses the pres-
ence of infection and more than one of the Systemic In-
flammatory Response Syndrome (SIRS) criteria including
the following: a) body temperature [>38 or <36 °C], b) heart
rate [>90 beats/min], c) hyper-ventilation [respiratory rate
>20 breaths/min or PaCo2 < 32 mmHg], and d) white blood
cell count [>12,000 cells/μL or <4000 cells/μL]. According
to this definition, ‘sepsis’ with organ dysfunction and ‘sepsis’
with acute circulatory failure with arterial hypotension have
been termed as ‘severe sepsis and ‘septic shock’, respectively
[1]. Although the joint presence of infection and SIRS cri-
teria has been widely adopted, their utility as a diagnostic
tool for identifying sepsis has been recognised to be limited
owing to high sensitivity and low specificity of these criteria
(i.e. they may manifest in the absence of infection, in pa-
tients with severe trauma, burns, and other inflammatory
disorders such as pancreatitis) [25, 18].
In 2001, the American College of Chest Physicians
(ACCP) and the Society of Critical Care Medicine (SCCM)
convened a consensus conference and updated the defin-
ition of sepsis by expanding the list of markers potentially
related to sepsis (e.g. inflammatory response, hemodynamic,
organ dysfunction, and tissue perfusion parameters) [1].
One important outcome of this conference was the intro-
duction of a ‘Predisposition, Infection, Response, and Organ
Dysfunction’ (PIRO) system for staging sepsis. For the pur-
pose of improving the diagnosis of sepsis, some authors sug-
gested that the original definition of sepsis should
additionally incorporate an evidence of organ dysfunction
which is a more specific sign to sepsis or severe sepsis [21,
25]. The original definition adopted in 1991 [24] is still
widely used. The difficulties in case definition and variations
in the definitions used substantially complicate the compari-
son and synthesis of findings across studies.
Risk factors and high-risk population subgroups
Several studies examined age, sex, and race disparities for de-
veloping sepsis and demonstrated that men compared to
women are more likely to have sepsis or severe sepsis [4, 9,
11, 10, 26]. Similarly, African-Americans are at higher risk
for developing severe sepsis compared to Caucasians (ad-
justed relative risk range 1.40–1.89) [4, 27, 28]. Moreover,
older age [19, 29] and certain chronic medical conditions
(HIV, alcohol abuse, cancer, lung/kidney disease, myocardial
infarction, diabetes, stroke, deep vein thrombosis, coronary
artery disease, hypertension) [29, 2, 30, 26] have also been
shown to be associated with a significantly greater risk for
sepsis. In their study, Hall et al. observed a 30-fold increase
in the incidence rate of sepsis or septicaemia amongst people
>85 years vs. those ≤65 years (271.2 per 10,000 vs. 9.5 per
10,000) [19]. In one US-based nationwide cohort study, the
risk of sepsis in cancer patients was almost 10 times as high
compared to the US general population without cancer (age-
and sex- adjusted RR= 9.77, 95 % CI 9.67, 9.88) [30].
Community-onset and hospital-acquired sepsis
Traditionally, sepsis has been classified into community-
onset and hospital-acquired (i.e. nosocomial) infection, de-
pending on the place of the infection’s acquisition [31, 32].
The two contexts of sepsis acquisition differ in terms of the
host characteristics (e.g. demographics, risk profile, resistance
patterns), pathogens, and outcomes [33–36]. For example, in
their study, Hoenigl and colleagues observed a significantly
higher 30-day (20.75 vs. 11.20 %, p= 0 · 001) and 90-day
(26.83 vs. 12.63 %, p < 0 · 001) mortality rates in people with
hospital-acquired vs. community-onset infection [34].
More recently, with increasing number of sepsis cases as-
sociated with outpatient treatment that takes place in com-
munities (e.g. nursing homes, dialysis, long-term home care
facilities), a new category of healthcare-associated sepsis has
been recognised and introduced [37, 38]. According to the
definition of healthcare-associated sepsis, the patient had to
have received a medical care in the community/outpatient
setting (e.g. intravenous therapy, wound care) 30 days before
the bloodstream infection, hospitalisation in acute care hos-
pital 90 days before the bloodstream infection, attendance of
hospital or haemodialysis clinic, or residence in a nursing
home or a long-term care facility [37]. Although nosocomial
and healthcare-associated sepsis are similar with respect to
source of infection, type of pathogens, susceptibility, and the
outcome, emerging empirical evidence has shown them to
be two distinct entities. Therefore, community-onset sepsis
has been further divided into healthcare-associated and
community-acquired sepsis [37–39, 34, 35].
The definition of community-onset sepsis has not been
consistent in the literature [39]. The most often used and
widely accepted definition specifies community-onset sep-
sis as one that manifests (positive blood culture and sys-
temic inflammatory response syndrome criteria) before or
within 48 h after hospital admission [31, 37, 34, 40, 36, 41].
According to this definition, a nosocomial (hospital-
acquired) infection is one that manifests more than
48 h after hospitalisation [37, 34, 40, 36, 41].
One important gap in the sepsis literature is the
scarcity of evidence on the incidence of sepsis as op-
posed to severe sepsis for which evidence is more
abundant [18]. Another limitation is that the majority
of studies have used hospital discharge databases
which do not allow to distinguish the findings
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between community-onset and hospital-acquired sep-
sis, which as noted above are different in population
distribution and outcome. The evidence on incidence
and risk factors of community-onset sepsis has not
been systematically reviewed, an evidence-base gap of
particular importance in planning for public-facing
interventions.
To address these gaps, this systematic review will
identify, appraise, and synthesise the empirical evidence
on the incidence and risk factors of community-onset
sepsis, severe sepsis, and septic shock.
Research question and aims of the systematic review
The aim of this review will be to systematically identify,
appraise, and synthesise the recent evidence on inci-
dence of community-onset sepsis, severe sepsis, or septic
shock in countries of the Western industrialised
world (North America, Australasia, and North/Western
Europe). The review focus will be limited to more recent
evidence from high-income countries (more relevant to
the UK practice) given the documented longitudinal
changes in the incidence, outcome, and implicated path-
ogens in sepsis [18] and modifications in the definition
of sepsis that have taken place in 1991 [24] and 2001 [1].
Therefore, only studies reporting the evidence on data
collected in 2002 or onwards will be sought.
To contribute to the aim of supporting PHE responsibil-
ities to evaluate the evidence base for a public-facing sep-
sis campaign, the specific review objectives will be the
following:
a) To catalogue and map in a tabular fashion the
relevant literature according to socio-demographic
characteristics and clinical risk factors in relation to
incidence of community-onset (e.g. healthcare-
associated, community-acquired) sepsis, severe sepsis,
and/or septic shock
b) To document overall and stratum-specific (by socio-
demographic characteristics, clinical risk factors)
incidence of community-onset (e.g. healthcare-
associated, community-acquired) sepsis, severe
sepsis, and/or septic shock
c) To compile and synthesise evidence on specific socio-
demographic, clinical, or laboratory characteristics as
potential risk factors for community-onset (e.g.
healthcare-associated, community-acquired) sepsis,
severe sepsis, and/or septic shock
Methods/Design
This systematic review protocol will be reported accord-
ing to recommendations from the Preferred Reporting
Items for Systematic Review and Meta-analysis Protocols
(PRISMA-P) 2015 statement [42].
Study eligibility criteria (primary studies)
Inclusion criteria
Study design Longitudinal prospective or retrospective
cohort studies; case-control studies.
Study setting Population- or hospital-based studies
considering community-onset cases separately; studies
conducted in North America, Australasia, and North/
Western Europe.
Population Community dwellers, hospitalised patients
(male of female) from a defined population of any age (except
for neonates) and health state with or without community-
onset sepsis at study baseline. The use of relevant ICD-9/10
codes [3, 4, 43] and established criteria for the diagnoses of
sepsis (e.g. the presence of infectious pathogen or blood-
stream infection plus two or more SIRS criteria as a direct
response to the infection), severe sepsis (e.g. sepsis compli-
cated by organ dysfunction), and septic shock (e.g. sepsis-
induced acute circulatory failure associated with persistent
arterial hypotension) [24, 1, 33, 44]. will be used to determine
inclusion. Those with community-onset sepsis will be eligible
for inclusion regardless whether they have healthcare-
associated (HCA; e.g. people receiving outpatient treatments
such as dialysis) or community-acquired (CA) sepsis.
Intervention/exposure 1 Any subgroup, patient charac-
teristic, or clinical parameter (e.g. age, sex, comorbidity,
heart rate, body temperature, altered mental status,
white blood cell count, creatinine, organ dysfunction
score) evaluated for association with risk of sepsis, se-
vere sepsis or septic shock.
Comparator/exposure 2 Any subgroup, patient charac-
teristic, or clinical/laboratory parameter used as the refer-
ence category to exposures in the exposure 1 group.
Outcome The occurrence of community-onset sepsis, se-
vere sepsis, and/or septic shock. This will allow variations
in sepsis definition including studies reporting confirmed
bloodstream infections plus SIRS criteria.
Outcome measures Odds, cumulative incidence pro-
portion (risk), incidence rate, and/or hazard rate of sep-
sis, severe sepsis, and/or septic shock.
Measures of association Odds ratio (OR), risk ratio (RR),
risk difference (RD), incidence rate ratio (IRR), and/or
hazard ratio.
Date of publication Studies reporting the evidence on
data collected in 2002 or onwards.
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Language of publication English.
Type of publication Full-text report.
Exclusion criteria
Study design Intervention studies (controlled or uncon-
trolled), prognostic studies (looking at associations between
putative prognostic factors and subsequent outcomes or
complications such as severe sepsis, septic shock, and/or
mortality in participants with sepsis), cross-sectional studies,
ecological studies, case series, case reports.
Publication type Abstracts, reviews (systematic or non-
systematic), editorials, letters, books, consensus state-
ments, or opinions. Reviews will be excluded as sources
of primary data but will be used to identify the original
studies contributing the evidence.
Publication language Any other than English. Non-
English publications will be excluded due to limited re-
sources. Although the inclusion of non-English studies is
likely to cover this topic more comprehensively, to the
best of our knowledge, we are not aware of any empirical
evidence informing on effects of language bias in system-
atic reviews of incidence of sepsis.
Population a) Study population with hospital-acquired
(nosocomial) sepsis; b) it cannot be determined if the
study population presented with community-onset or
hospital-acquired sepsis; c) results on populations with
community-onset and hospital-acquired sepsis are mixed
(not stratified); d) bloodstream infection (BSI) not associ-
ated with sepsis/SIRS, severe sepsis (organ dysfunction),
or septic shock (circulatory failure and persistent arterial
hypotension); e) study population representing a specific
subgroup defined by clinical condition (e.g. cancer, coron-
ary heart disease, sepsis/severe sepsis), and f) neonates
Outcomes Studies not reporting incidence/risk of sepsis
(in absolute or relative terms), studies reporting only
single site infections, or single infecting species, studies
reporting only economic evaluation and/or cost-effect-
iveness outcomes, diagnostic accuracy or prognostic
ability of biomarkers, or only mortality (including case-
fatality).
Search strategy and literature sources
We will search Ovid MEDLINE and Ovid Embase from
2002 using a combination of subject headings and key-
words for sepsis and related terms combined with terms
for epidemiology and related concepts and finally com-
bined this with terms for studies in community-based set-
tings. The Ovid MEDLINE search strategy will also be
adapted for Ovid Embase. The searches will be limited to
English-language documents, and documents such as
comments, letters, editorials, or meeting abstracts will be
excluded.
Additionally, we will seek for unpublished literature
through the following sources: a) hand search of refer-
ence lists of potentially eligible articles, b) relevant
websites of organisations dealing with sepsis (Inter-
national Sepsis Forum, Sepsis Trust UK, Sepsis Alli-
ance, Centre for Disease Control, World Sepsis Day),
c) contacting experts/researchers in the field, d) theses
database (index to theses), and e) Google Scholar
(government or other reports).
We will not search sources of conference proceedings,
since they represent abstracts (with no corresponding
full texts) which do not provide sufficient information
allowing to ascertain and verify a) how sepsis was diag-
nosed, b) whether study population had community-
onset or hospital-acquired sepsis, and c) needed details
on incidence and risk factors.
More details on search strategy and sources are pro-
vided in Appendix 1.
Study selection and data management
All bibliographic records (i.e. publications) identified
through our searches (electronic or hand-searched)
will be compiled and then de-duplicated in a special
bibliographic endnote database. Afterwards, two re-
viewers (AT and NM) using a pre-defined piloted
screening form of the eligibility criteria will independ-
ently screen all the titles and abstracts of corresponding
publications. Any disagreements regarding inclusion or
exclusion of any given title/abstract will be discussed
and resolved via consensus. Then, the same two re-
viewers will examine full-text reports of all potentially
relevant publications passing the title/abstract level of
screening for their eligibility. Any disagreements re-
garding the eligibility of the full text reports will be dis-
cussed and resolved through a consensus agreement or
a third party adjudication.
Differentiation of community-onset sepsis (health-
care-associated, community-acquired) from hospital-
acquired sepsis will be operationalized by relying on
definitions used in individual primary studies indicat-
ing the presence of community-onset sepsis. We
expect some variation across studies in definitions of
community-onset sepsis so that adopting a single pre-
specified fixed definition might exclude relevant data.
For example, certain authors define community-onset sep-
sis as one that manifests before hospital admission or
within 48 h after hospital admission [34, 40, 36, 41]. Other
authors define community-onset sepsis if it manifests
within 24–28 h of hospital admission [45, 33, 46]. Some
other statements may only suggest the presence of
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community-onset sepsis ranging from ‘patients hospi-
talized with sepsis’ to ‘sepsis-related hospitalization’
[47, 28]. Alternatively, other authors may additionally
report study exclusion criteria for hospital-acquired
sepsis [47].
The study selection process and reasons for exclusion
at full-text screening level will be presented in the
PRISMA study flow diagram (Appendix 2) [48].
Data extraction
One of two reviewers (AT and NM) using pre-defined
data extraction sheets will extract relevant information
from included studies. The extracted data will include
information on study (e.g. author name, year of publica-
tion, country of conduct, design, study setting, sample
size, duration of follow-up, study quality items), potential
risk factors (e.g. participant socio-demographic characteris-
tics, comorbidities, health care procedure or intervention,
laboratory marker, clinical symptom or parameter), and
outcomes (e.g. definition of sepsis and related out-
comes, type of pathogen, place and time of sepsis ac-
quisition, type of health care procedure if used as
outpatient treatment, the frequency of occurrence
measures for sepsis, severe sepsis, and/or septic
shock). Any missing statistical parameters of import-
ance (e.g. cumulative incidence proportion, incidence
rate, odds, risk ratio, incidence rate ratio, and odds
ratio) and variability measures (e.g. 95 % confidence
intervals, p values) will be calculated, if data permits,
or authors of the primary studies will be contacted.
All calculated or derived data will be denoted as
‘calculated’ and will be incorporated in the extraction
sheets.
The data extracted will be cross-checked. Any dis-
agreements regarding the extracted data will be re-
solved between the two reviewers or through a
consensus agreement or adjudication of a third party,
if needed (Appendix 3).
Quality (risk of bias) assessment
Methodological quality (or risk of bias) of included
studies will be appraised by two independent
reviewers (AT and NM) using two checklists devel-
oped and validated by the Scottish Intercollegiate
Guidelines Network (SIGN) separately for cohort
[49] and case-control studies [50]. We selected these
tools based on the guidance for evidence-based deci-
sion making in infectious diseases epidemiology, pre-
vention, and control proposed by Harder and
colleagues [51].
Both the cohort (16 items) and case-control (13
items) study checklists address five domains/sources
of bias: 1) study research question; 2) participant
selection (e.g. sampling bias, differential non-
participation, sample attrition/losses to follow-up,
incomplete data assessment); 3) information (perform-
ance, detection) bias (e.g. outcome and/or exposure
measurement and ascertainment, recall bias); 4) con-
founding, statistical analysis; and 5) an overall assess-
ment of the study (i.e. summary judgement on
internal and external validity of study findings). The
response to each item can be recorded as ‘yes’, ‘no’,
‘can’t say’, or ‘doesn’t apply’. The overall methodo-
logical quality of each included study will be based on
the number of satisfied items (response ‘yes’) and will
be rated as follows:
 High quality++ (≥12 items rated as ‘yes’ for cohort
studies and ≥10 items rated as ‘yes’ for case-control
studies = little or no risk of bias; results unlikely to
be changed by further research)
 Acceptable quality+ (6–11 items rated as ‘yes’ for
cohort studies and 5–9 items rated as ‘yes’ for
case-control studies = most criteria met; some
flaws in the study with an associated risk of bias;
conclusions may change in the light of further
studies)
 Low quality 0 (0–5 items rated as ‘yes’ for cohort
studies and 0–4 items rated as ‘yes’ for case-
control studies = either most criteria not met, or
significant flaws relating to key aspects of study
design; conclusions likely to change in the light of
further studies).
The quality appraisals will be cross-checked, and any
disagreements will be resolved by a consensus-based dis-
cussion or through a third party, if necessary. The over-
all and individual item-specific quality assessment
ratings for each study will be presented in Appendix 4
(Table 1 [cohort studies] and Table 2 [case-control
studies]).
Data analysis and synthesis
The collected evidence (study, participant, and out-
come characteristics) will be narratively synthesised,
appraised, and organised in summary tables and text.
The evidence for incidence (global, national, and re-
gional) and subgroups/risk factors in relation to the
occurrence of sepsis will be presented separately.
Where possible, the community-onset sepsis studies
will be stratified by those of healthcare-associated and
community-acquired sepsis.
The incidence and/or effect estimates with 95 %
confidence intervals (95 % CIs) will be ascertained and
presented in tables and figures separately for sepsis,
severe sepsis, and septic shock (i.e. forest plots) as
available. These outcomes will be further stratified by
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age, sex, study setting (e.g. hospital ward, nursing care
facility, intensive-care unit), and other important char-
acteristics, if data permits. Evidence on risk factors
will be summarised separately for case-control and co-
hort studies.
The study results will be meta-analysed if sufficient
degree of similarity exists across characteristics of
populations, definitions of exposure and case-control
groups, and types of outcomes of sepsis occurrence.
The estimates of summary dichotomous outcome
measures (e.g. risk or odds ratios) will be pooled
using a DerSimonian and Laird random-effects model
(no rare events, >10.0 %), Mantel-Haenszel fixed-effects
model (low event rates, 5.0 %–10.0 %), or Peto
fixed-effects model (very low event rates, < 5.0 % or
zero events) [52]. The choice of random-effects
model is based on the expectation that there will be
clinical and methodological diversity across included
studies.
The visual inspection of the forest plots and statistical
parameters (Chi-square based p value <0.10; I2 > 50 %)
will be used to judge the extent of statistical heterogen-
eity across the estimates of pooled studies. The hetero-
geneity will be explored through subgroup analysis (e.g.
age, sex, underlying comorbidity) and sensitivity analysis
(by study design, summary quality/risk of bias rating,
study setting).
The extent of publication bias will be examined if the
number of studies reporting quantitative measure(s) of
the association between a risk factor and sepsis occur-
rence is sufficient for the inspection of funnel plot asym-
metry [53].
Rating overall quality of evidence
The overall quality of the body of evidence on risk
factors and frequency measures of sepsis occurrence
will not be graded because there is no formal and
validated grading system directly applicable to the
type of evidence synthesised in this review. The
widely accepted and used system suggested by the
Grading of Recommendations, Assessment, Develop-
ment, and Evaluation (GRADE) Working Group is
ideally applicable to grading the quality of evidence,
i.e. multiple patient-oriented outcomes across stud-
ies evaluating and comparing different health care
interventions [54] and diagnostic accuracy of tests
[55].
Discussion
This systematic review will identify and summarise the
relevant evidence on the burden of community-onset
sepsis in terms of incidence and risk factors. Major find-
ings of this systematic review will be summarised in
conjunction with the study methodological quality.
Strengths and limitations (e.g. exclusion of non-English
studies, conference abstracts) of the review will be dis-
cussed and gaps in the evidence will also be highlighted.
The findings of this review and those of other similar re-
views will be compared (if identified) for the degree of
consistency.
Timeliness and accuracy of diagnosis of sepsis are
both crucial aspects for improving the patient’s out-
come. The findings will be discussed with a view to
better informing PHE recommendations on public-
facing campaigns to improve timely presentation and
diagnosis of sepsis in the community as well as con-
tribute more widely as a basis to future research and
policy on improving public health planning.
Appendix 1
Search strategy for Ovid MEDLINE
1. exp Sepsis/
2. (sepsis or septic?emi* or bact?eremi* or
disseminated candidiasis or fung?emi* or septic
shock).tw.




7. exp Population Surveillance/
8. exp epidemiologic studies/
9. exp odds ratio/or exp risk/
10. exp Socioeconomic Factors/
11. exp Ethnic Groups/
12. (epidemiology or incidence or risk or mortality or
burden or odds ratio or prevalence).tw.
13.4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14.3 and 13
15. ((community or population) adj2 (onset or acqui*
or based)).tw.
16. long term care facilit*.tw.
17. (nursing home* or care home*).tw.
18. exp Residential Facilities/
19. (prehospital or pre-hospital).tw.
20. out-of-hospital.tw.
21. (sepsis related hospitalization or sepsis related
hospitalisation).tw.
22. (hospitalised with sepsis or hospitalized with
sepsis).tw.
23. admitted with sepsis.tw.
24. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 14 and 24
26. limit 25 to (english language and yr = “2002 -Current”)
27. (comment or letter or editorial).pt.
28. 26 not 27
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Appendix 2
Fig. 1 PRISMA study flow diagram
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Appendix 3
Data extraction sheet for included primary study reports
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Appendix 4
Methodological quality of included studies
Table 1 Methodological quality (risk of bias) in cohort studies (16 items)















The study addresses an appropriate and clearly focused question (Item 1)
Selection of subjects
The two groups being studied are selected from source populations that
are comparable in all respects other than the factor under investigation (Item 2)
The study indicates how many of the people asked to take part did so, in each
of the groups being studied (Item 3)
The likelihood that some eligible subjects might have the outcome at the time
of enrolment is assessed and taken into account in the analysis (Item 4)
What percentage of individuals or clusters recruited into each arm of the study
dropped out before the study was completed (Item 5)
Comparison is made between full participants and those lost to follow-up, by
exposure status (Item 6)
Assessment
The outcomes are clearly defined (Item 7)
The assessment of outcome is made blind to exposure status. If the study is
retrospective this may not be applicable (Item 8)
Where blinding was not possible, there is some recognition that knowledge
of exposure status could have influenced the assessment of outcome (Item 9)
The method of assessment of exposure is reliable (Item 10)
Evidence from other sources is used to demonstrate that the method of
outcome assessment is valid and reliable (Item 11)
Exposure level or prognostic factor is assessed more than once (Item 12)
Confounding
The main potential confounders are identified and taken into account in the
design and analysis (Item 13)
Statistical analysis
Have confidence intervals been provided? (Item 14)
Overall assessment of the study
Taking into account clinical considerations, your evaluation of the methodology
used, and the statistical power of the study, do you think there is clear evidence
of an association between exposure and outcome? (Item 15)
Are the results of this study directly applicable to the patient group targeted in this
guideline? (Item 16)
Summary quality (risk of bias) rating
Possible responses to each item: yes, no, can’t say, or doesn’t apply
≥12 items rated as ‘yes’ - high quality++ (little or no risk of bias; results unlikely to be changed by further research)
6–11 items rated as ‘yes’ - acceptable quality+ (most criteria met; some flaws in the study with an associated risk of bias; conclusions may change in the light of further studies)
0–5 items rated as ‘yes’ - low quality 0 (either most criteria not met, or significant flaws relating to key aspects of study design; conclusions likely to change in the
light of further studies)
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Table 2 Methodological quality (risk of bias) in case-control studies (13 items)















The study addresses an appropriate and clearly focused question (Item 1)
Selection of subjects
The cases and controls are taken from comparable populations (Item 2)
The same exclusion criteria are used for both cases and controls (Item 3)
What percentage of each group (cases and controls) participated in the study?
(Item 4)
Comparison is made between participants and non-participants to establish
their similarities or differences (Item 5)
Cases are clearly defined and differentiated from controls (Item 6)
It is clearly established that controls are non-cases (Item 7)
Assessment
Measures will have been taken to prevent knowledge of primary exposure
influencing case ascertainment (Item 8)
Exposure status is measured in a standard, valid and reliable way (Item 9)
Confounding
The main potential confounders are identified and taken into account in the
design and analysis (Item 10)
Statistical analysis
Confidence intervals are provided (Item 11)
Overall assessment of the study
Taking into account clinical considerations, your evaluation of the methodology
used, and the statistical power of the study, do you think there is clear evidence
of an association between exposure and outcome? (Item 12)
Are the results of this study directly applicable to the patient group targeted
by this guideline? (Item 13)
Summary quality (risk of bias) rating
Possible responses to each item: yes, no, can’t say, or doesn’t apply
≥10 items rated as ‘yes’ - high quality++ (little or no risk of bias; results unlikely to be changed by further research)
5–9 items rated as ‘yes’ - acceptable quality+ (most criteria met; some flaws in the study with an associated risk of bias; conclusions may change in the light of further studies)
0–4 items rated as ‘yes’ - low quality 0 (either most criteria not met, or significant flaws relating to key aspects of study design; conclusions likely to change in the
light of further studies)
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